Tag Archive for: Bristol-Myers Squibb

AstraZeneca said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices.

Nearly two million people are living with moderate to severe plaque psoriasis in the U.S., but patients often face stigma and feel misunderstood by those around them.

Today BMS said its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.

The drug was being studied in patients with types of urothelial carcinoma who are eligible for cisplatin-based chemotherapy.

Bristol Myers Squibb Co. (BMY.N) on Friday sued the U.S. government in an attempt to halt the Medicare drug price negotiation program that analysts believe will involve one of its top-selling medicines, saying it violates the Fifth and First Amendments to the U.S. Constitution.

The aim of the Lupus Nexus is to transform lupus research and drug development through unprecedented information exchange capabilities. The platform will provide a collaborative solution that is inclusive of diverse patient populations disproportionally affected by lupus.

“Bristol Myers Squibb’s business model is constantly evolving to support our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases,” a spokesperson stated. “As we move forward in 2023, we are continuing to deliver on our long-term business strategy by aligning resources to best support our operating model and our portfolio evolution.”

Bristol Myers Squibb said on Wednesday evening its CEO Giovanni Caforio would step down in November and will be replaced by current Chief Commercialization Officer Chris Boerner, as the drugmaker contends with increasing generic competition for its top-selling drugs.

The deal could be worth more than $1 billion, starting with an upfront payment of $22.75 million.

Leaked data from the Phase III CARTITUDE-4 trial showed Johnson & Johnson’s and Legend Biotech’s Carvykti (ciltacabtagene autoleucel) performed much better than expected in patients with multiple myeloma (MM), according to reporting by STAT News.